Pacira Pharmaceuticals Inc (PCRX)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	513,796	515,941	532,183	542,918	655,823	713,999	721,878	729,743	674,530	326,146	321,708	317,338	313,030	456,464	314,182	310,078	306,045	302,081	298,185	294,356
Total assets	US$ in thousands	1,574,390	1,534,460	1,542,380	1,523,420	1,681,200	1,734,360	1,733,990	1,891,480	2,075,350	1,356,000	1,325,830	1,287,550	1,274,510	1,220,270	866,111	821,379	831,065	807,489	787,843	719,156
Debt-to-assets ratio		0.33	0.34	0.35	0.36	0.39	0.41	0.42	0.39	0.33	0.24	0.24	0.25	0.25	0.37	0.36	0.38	0.37	0.37	0.38	0.41

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $513,796K ÷ $1,574,390K
= 0.33

The debt-to-assets ratio of Pacira BioSciences Inc has shown a decreasing trend over the past two years, indicating an improvement in the company's debt management and financial health. In Q4 2023, the ratio stood at 0.33, down from 0.41 in Q4 2022. This suggests that the company has been reducing its debt relative to its total assets, which may indicate a lower financial risk and increased solvency. It is important to continue monitoring this trend to ensure the company's ongoing financial stability and ability to meet its debt obligations.